What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals?

Autor: Christophe Bintener, Michael Sharwood Smith, Michele Potashman, Amanda Ly, Alex McKeown, Christoph Jindra, Anders Gustavsson, Emilse Roncancio-Diaz, Cathie Sudlow, Olin Janssen, Anna Ponjoan, Claire Tochel, Stephanie J.B. Vos, Isabella Friis Jørgensen, Buket Öztürk, Catherine Reed, Josep Garre-Olmo, Mia Nelson, Christin Bexelius, Helen Baldwin, Enrico R. Fantoni

Publikováno v: Tochel, C, Smith, M, Baldwin, H, Gustavsson, A, Ly, A, Bexelius, C, Nelson, M, Bintener, C, Fantoni, E, Garre-Olmo, J, Janssen, O, Jindra, C, Jørgensen, I F, McKeown, A, Öztürk, B, Ponjoan, A, Potashman, M H, Reed, C, Roncancio-Diaz, E, Vos, S & Sudlow, C 2019, ' What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review ', Alzheimer's & Dementia, vol. 11, pp. 231-247 . https://doi.org/10.1016/j.dadm.2018.12.003
Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Alzheimers & Dementia: Diagnosis, Assessment & Disease Monitoring
Tochel, C, Smith, M, Baldwin, H, Gustavsson, A, Ly, A, Bexelius, C, Nelson, M, Bintener, C, Fantoni, E, Garre-Olmo, J, Janssen, O, Jindra, C, Jorgensen, I, McKeown, A, Ozturk, B, Ponjoan, A, Potashman, M, Reed, C, Roncancio-Diaz, E, Vos, S & Sudlow, C 2019, ' What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review ', Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring . https://doi.org/10.1016/j.dadm.2018.12.003
Tochel, C, Smith, M, Baldwin, H, Gustavsson, A, Ly, A, Bexelius, C, Nelson, M, Bintener, C, Fantoni, E, Garre-Olmo, J, Janssen, O, Jindra, C, Jørgensen, I F, McKeown, A, Öztürk, B, Ponjoan, A, Potashman, M H, Reed, C, Roncancio-Diaz, E, Vos, S, Sudlow, C & ROADMAP consortium 2019, ' What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review ', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 11, pp. 231-247 . https://doi.org/10.1016/j.dadm.2018.12.003
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 11(1), 231-247. Elsevier BV
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, Vol 11, Iss 1, Pp 231-247 (2019)

Introduction: Clinical trials involving patients with Alzheimer’s disease (AD) continue to try to identify disease-modifying treatments. Although trials are designed to meet regulatory and registration requirements, many do not measure outcomes of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b9fc902e29a50872ed92ca7654b159
https://cris.maastrichtuniversity.nl/en/publications/0f468330-2ae5-4972-b0a4-e3b057ce4213

A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease

Autor: Anastasia Chalkidou, Enrico R. Fantoni, Gill Farrar, John T. O' Brien, Alexander Hammers

Publikováno v: Journal of Alzheimer's Disease

BACKGROUND: Amyloid PET (aPET) imaging could improve patient outcomes in clinical practice, but the extent of impact needs quantification. OBJECTIVE: To provide an aggregated quantitative analysis of the value added by aPET in cognitively impaired su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d3589b75021d25342a78b6269eb3993

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques

Autor: Enrico R. Fantoni, Stephen Salloway, Milos D. Ikonomovic, Gill Farrar

Publikováno v: Alzheimer’s Research & Therapy, Vol 10, Iss 1, Pp 1-4 (2018)

Background The performance of [18F]flutemetamol amyloid PET against histopathological standards of truth was the subject of our recent article in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (2017;9:25–34). Main body This vi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5243a373d99c5da438b6d3a2b5b13f17
https://doi.org/10.1186/s13195-018-0387-6

[P1–381]: MEASUREMENT OF PATHOLOGICAL AMYLOID IN ROUTINE CLINICAL ASSESSMENT: THE CLINICAL IMPACT OF VISUAL [ 18 F]FLUTEMETAMOL PET AND CSF ANALYSIS

Autor: Enrico R. Fantoni, Nenad Bogdanovic, Gill Farrar

Publikováno v: Alzheimer's & Dementia. 13

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a348a5041f0df8f42d392694d76a6bb1
https://doi.org/10.1016/j.jalz.2017.06.397